The Cocktail Report (sound really smart around your friends):
STAREE is the largest randomized statin trial ever run in adults over 70 without heart disease, published August 29 in the New England Journal of Medicine.
Nearly 10,000 community-dwelling Australians took atorvastatin 40 mg or a placebo for a median of about six years.
Major cardiovascular events fell 30 percent in the statin group.
The other main endpoint, survival free of death, dementia, or lasting disability, showed no benefit at all.
Serious side effects were similar between groups, but muscle, liver, and diabetes-related problems all showed up more often on the statin.
If you are in your seventies without a diagnosis of heart disease, diabetes, or dementia, your doctor may have already asked whether you want to start a statin. Until this month, no large randomized trial could guide that answer.
Now we do. It is called STAREE, and the results are more complicated than the headlines suggest.
Researchers at Monash University and general practices across Australia enrolled 9,971 people at least 70 years old. The average age was 74.7 and just over half were women.
Half received atorvastatin 40 mg once a day and half received an identical placebo. Neither the participants nor their doctors knew who got which.
Everyone was followed for a median of 5.9 years.
The trial had two primary endpoints. That matters, because the two results point in different directions.
The first endpoint was major cardiovascular events, meaning heart attacks, strokes, and cardiovascular deaths. In the statin group, 297 people had one versus 412 on placebo.
That is a 30 percent lower relative risk, and it is what the media called a landmark result.
The second endpoint asked whether the statin extended the years you would want to live, defined as being alive, free of dementia, and free of persistent physical disability. On that measure, 637 people in the statin group had one of those bad outcomes versus 676 on placebo, a difference that was not statistically meaningful.
The two results are worth reading together. Fewer heart attacks and strokes did not translate into more years of independent life.
Safety was reassuring in the aggregate. Serious adverse events occurred in 2.7 percent of both groups.
That said, muscle problems, liver problems, and new diabetes were all reported more often in people taking the statin. These are the exact side effects patients have long complained about.
To be candid, this trial does not tell you whether to take a statin. It tells you what a statin buys and what it does not.
If your concern is a heart attack or stroke in your seventies, the data now show meaningful protection.
If your concern is holding on to independent function into your eighties, this trial found no evidence that a statin helps with that goal.
Why Should You Care?
If you are past 70 and being offered a statin for prevention, this is the trial your doctor should walk through with you. The heart benefit is real, but so is the fact that it did not translate into more years free of dementia or disability.
1. Zoungas S, et al. Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults. New England Journal of Medicine, August 29, 2026. DOI 10.1056/NEJMoa2607314. https://www.nejm.org/doi/10.1056/NEJMoa2607314
2. STAREE Trial (ClinicalTrials.gov NCT02099123). https://clinicaltrials.gov/study/NCT02099123
3. STAREE Trial Cuts Major CV Events by 30 Percent in Older Adults. Medscape, August 29, 2026. https://www.medscape.com/viewarticle/staree-trial-atorvastatin-cuts-major-cv-events-30-older-2026a1000ukk
